The Parkinsonian mimetic, 6-OHDA, impairs axonal transport in dopaminergic axons

Molecular Neurodegeneration

Volumn 9, Issue 1, 2014, Pages

  Lu, Xi ^a   Kim Han, Jeong Sook ^b   Harmon, Steve ^b   Sakiyama Elbert, Shelly E ^a   O'Malley, Karen L ^b  

^a WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Microfluidic devices; Microtubule; Mitochondria; Neurodegeneration; Parkinson's disease

Indexed keywords

GREEN FLUORESCENT PROTEIN; OXIDOPAMINE; SYNAPTOPHYSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; BRIGHT FIELD MICROSCOPY; CELL DEATH; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EMBRYO; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL VOLUME; MOUSE; NERVE FIBER DEGENERATION; NERVE FIBER TRANSPORT; NONHUMAN; PARKINSON DISEASE; RETROGRADE DEGENERATION; SYNAPSE VESICLE;

PARKINSONIA;

ADRENERGIC AGENTS; ANIMALS; AXONAL TRANSPORT; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; MICE; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; MITOCHONDRIA; NERVE DEGENERATION; OXIDOPAMINE; PARKINSON DISEASE;

EID: 84900501666     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-9-17     Document Type: Article

References (53)

1. Axon degeneration in Parkinson's disease. Burke RE, O'Malley K, Exp Neurol 2013 246 72 83 22285449
2. Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis. Riederer P, Wuketich S, J Neural Transm 1976 38 277 301 10.1007/BF01249445 956814
3. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Chu Y, Morfini GA, Langhamer LB, He Y, Brady ST, Kordower JH, Brain 2012 135 2058 2073 10.1093/brain/aws133 22719003
4. Axonal self-destruction and neurodegeneration. Raff MC, Whitmore AV, Finn JT, Science 2002 296 868 871 10.1126/science.1068613 11988563 (Pubitemid 34464884)
5. 1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C. Morfini G, Pigino G, Opalach K, Serulle Y, Moreira JE, Sugimori M, Llinas RR, Brady ST, Proc Natl Acad Sci U S A 2007 104 2442 2447 10.1073/pnas.0611231104 17287338 (Pubitemid 46391416)
6. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, Bogdanov M, Przedborski S, Beal MF, Burke RE, Li C, Nat Neurosci 2009 12 826 828 10.1038/nn.2349 19503083
7. Parkinson's disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons. Saha AR, Hill J, Utton MA, Asuni AA, Ackerley S, Grierson AJ, Miller CC, Davies AM, Buchman VL, Anderton BH, Hanger DP, J Cell Sci 2004 117 1017 1024 10.1242/jcs.00967 14996933 (Pubitemid 38456084)
8. PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Wang X, Winter D, Ashrafi G, Schlehe J, Wong YL, Selkoe D, Rice S, Steen J, LaVoie MJ, Schwarz TL, Cell 2011 147 893 906 10.1016/j.cell.2011.10.018 22078885
9. A microdevice platform for visualizing mitochondrial transport in aligned dopaminergic axons. Lu X, Kim-Han JS, O'Malley KL, Sakiyama-Elbert SE, J Neurosci Methods 2012 209 35 39 10.1016/j.jneumeth.2012.05.021 22652340
10. The parkinsonian mimetic, MPP+, specifically impairs mitochondrial transport in dopamine axons. Kim-Han JS, Antenor-Dorsey JA, O'Malley KL, J Neurosci 2011 31 7212 7221 10.1523/JNEUROSCI.0711-11.2011 21562285
11. Cytosolic LC3 ratio as a quantitative index of macroautophagy. Kadowaki M, Karim MR, Methods Enzymol 2009 452 199 213 19200884
12. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna JM, Prog Neurobiol 2001 65 135 172 10.1016/S0301-0082(01)00003-X 11403877 (Pubitemid 32524182)
13. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Araki T, Sasaki Y, Milbrandt J, Science 2004 305 1010 1013 10.1126/science.1098014 15310905 (Pubitemid 39071777)
14. LC3, an autophagosome marker, can be incorporated into protein aggregates independent of autophagy: caution in the interpretation of LC3 localization. Kuma A, Matsui M, Mizushima N, Autophagy 2007 3 323 328 17387262 (Pubitemid 46986336)
15. Quantitative analysis of membrane potentials. Ward MW, Methods Mol Biol 2010 591 335 351 10.1007/978-1-60761-404-3-20 19957140
16. Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. Lotharius J, Dugan LL, O'Malley KL, J Neurosci 1999 19 1284 1293 9952406 (Pubitemid 29088911)
17. 6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. Hanrott K, Gudmunsen L, O'Neill MJ, Wonnacott S, J Biol Chem 2006 281 5373 5382 16361258 (Pubitemid 43847631)
18. Striatal 6-hydroxydopamine induces apoptosis of nigral neurons in the adult rat. Marti MJ, Saura J, Burke RE, Jackson-Lewis V, Jimenez A, Bonastre M, Tolosa E, Brain Res 2002 958 185 191 10.1016/S0006-8993(02)03694-6 12468044 (Pubitemid 35441227)
19. Akt suppresses retrograde degeneration of dopaminergic axons by inhibition of macroautophagy. Cheng HC, Kim SR, Oo TF, Kareva T, Yarygina O, Rzhetskaya M, Wang C, During M, Talloczy Z, Tanaka K, Komatsu M, Kobayashi K, Okano H, Kholodilov N, Burke RE, J Neurosci 2011 31 2125 2135 10.1523/JNEUROSCI.5519-10.2011 21307249
20. Parkinson's disease involves autophagy and abnormal distribution of cathepsin L. Li L, Wang X, Fei X, Xia L, Qin Z, Liang Z, Neurosci Lett 2011 489 62 67 10.1016/j.neulet.2010.11.068 21134415
21. Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Glinka YY, Youdim MB, Eur J Pharmacol 1995 292 329 332 7796873
22. Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP + -induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK. Choi WS, Yoon SY, Oh TH, Choi EJ, O'Malley KL, Oh YJ, J Neurosci Res 1999 57 86 94 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.0.CO;2-E 10397638 (Pubitemid 29293582)
23. Axon degeneration: molecular mechanisms of a self-destruction pathway. Wang JT, Medress ZA, Barres BA, J Cell Biol 2012 196 7 18 10.1083/jcb.201108111 22232700
24. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Lin MT, Beal MF, Nature 2006 443 787 795 10.1038/nature05292 17051205 (Pubitemid 44622683)
25. 6-OHDA generated ROS induces DNA damage and p53- and PUMA-dependent cell death. Bernstein AI, Garrison SP, Zambetti GP, O'Malley KL, Mol Neurodegener 2011 6 2 10.1186/1750-1326-6-2 21211034
26. Oxidative stress-triggered unfolded protein response is upstream of intrinsic cell death evoked by parkinsonian mimetics. Holtz WA, Turetzky JM, Jong YJ, O'Malley KL, J Neurochem 2006 99 54 69 10.1111/j.1471-4159.2006.04025.x 16987235 (Pubitemid 44395130)
27. Molecular mechanisms of 6-hydroxydopamine-induced cytotoxicity in PC12 cells: involvement of hydrogen peroxide-dependent and -independent action. Saito Y, Nishio K, Ogawa Y, Kinumi T, Yoshida Y, Masuo Y, Niki E, Free Radic Biol Med 2007 42 675 685 10.1016/j.freeradbiomed.2006.12.004 17291991 (Pubitemid 46205147)
28. Cell stress induced by the parkinsonian mimetic, 6-hydroxydopamine, is concurrent with oxidation of the chaperone, ERp57, and aggresome formation. Kim-Han JS, O'Malley KL, Antioxid Redox Signal 2007 9 2255 2264 10.1089/ars.2007.1791 17848102 (Pubitemid 350059016)
29. Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons. Holtz WA, O'Malley KL, J Biol Chem 2003 278 19367 19377 10.1074/jbc.M211821200 12598533 (Pubitemid 36799332)
30. Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. Ryu EJ, Harding HP, Angelastro JM, Vitolo OV, Ron D, Greene LA, J Neurosci 2002 22 10690 10698 12486162 (Pubitemid 36005143)
31. Puma and p53 play required roles in death evoked in a cellular model of Parkinson disease. Biswas SC, Ryu E, Park C, Malagelada C, Greene LA, Neurochem Res 2005 30 839 845 10.1007/s11064-005-6877-5 16187218 (Pubitemid 41413940)
32. Activation of p53 signaling initiates apoptotic death in a cellular model of Parkinson's disease. Nair VD, Apoptosis 2006 11 955 966 10.1007/s10495-006- 6316-3 16544096 (Pubitemid 43876826)
33. The Wld(S) mutation delays anterograde, but not retrograde, axonal degeneration of the dopaminergic nigro-striatal pathway in vivo. Cheng HC, Burke RE, J Neurochem 2010 113 683 691 10.1111/j.1471-4159.2010.06632.x 20132467
34. Wlds-mediated protection of dopaminergic fibers in an animal model of Parkinson disease. Sajadi A, Schneider BL, Aebischer P, Curr Biol 2004 14 326 330 10.1016/j.cub.2004.01.053 14972684 (Pubitemid 38300211)
35. The progressive nature of Wallerian degeneration in wild-type and slow Wallerian degeneration (WldS) nerves. Beirowski B, Adalbert R, Wagner D, Grumme DS, Addicks K, Ribchester RR, Coleman MP, BMC Neurosci 2005 6 6 10.1186/1471-2202-6-6 15686598 (Pubitemid 41418268)
36. Axonal stress kinase activation and tau misbehavior induced by kinesin-1 transport defects. Falzone TL, Stokin GB, Lillo C, Rodrigues EM, Westerman EL, Williams DS, Goldstein LS, J Neurosci 2009 29 5758 5767 10.1523/JNEUROSCI.0780- 09.2009 19420244
37. Coupling of kinesin steps to ATP hydrolysis. Hua W, Young EC, Fleming ML, Gelles J, Nature 1997 388 390 393 10.1038/41118 9237758 (Pubitemid 27334819)
38. Oxidative stress inhibits axonal transport: implications for neurodegenerative diseases. Fang C, Bourdette D, Banker G, Mol Neurodegener 2012 7 29 10.1186/1750-1326-7-29 22709375
39. MPP + -induces PUMA- and p53-dependent, but ATF3-independent cell death. Bernstein AI, O'Malley KL, Toxicol Lett 2013 219 93 98 10.1016/j.toxlet.2013.03. 003 23500530
40. The role of axonopathy in Parkinson's disease. O'Malley KL, Exp Neurobiol 2010 19 115 119 10.5607/en.2010.19.3.115 22110350
41. WldS but not Nmnat1 protects dopaminergic neurites from MPP + neurotoxicity. Antenor-Dorsey JA, O'Malley KL, Mol Neurodegener 2012 7 5 10.1186/1750-1326-7-5 22315973
42. PARK6 PINK1 mutants are defective in maintaining mitochondrial membrane potential and inhibiting ROS formation of substantia nigra dopaminergic neurons. Wang HL, Chou AH, Wu AS, Chen SY, Weng YH, Kao YC, Yeh TH, Chu PJ, Lu CS, Biochim Biophys Acta 1812 2011 674 684
43. PINK1 and Parkin flag Miro to direct mitochondrial traffic. Kane LA, Youle RJ, Cell 2011 147 721 723 10.1016/j.cell.2011.10.028 22078873
44. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. Narendra D, Tanaka A, Suen DF, Youle RJ, J Cell Biol 2008 183 795 803 10.1083/jcb.200809125 19029340
45. Mitochondrial quality control mediated by PINK1 and Parkin: links to parkinsonism. Narendra D, Walker JE, Youle R, Cold Spring Harb Perspect Biol 2012 4 011338 23125018
46. Parkin- and PINK1-Dependent Mitophagy in Neurons: Will the Real Pathway Please Stand Up? Grenier K, McLelland GL, Fon EA, Front Neurol 2013 4 100 23882257
47. Impairment of Atg5-dependent autophagic flux promotes paraquat- and MPP(+)-induced apoptosis but not rotenone or 6-hydroxydopamine toxicity. Garcia-Garcia A, Anandhan A, Burns M, Chen H, Zhou Y, Franco R, Toxicol Sci 2013 136 166 182 10.1093/toxsci/kft188 23997112
48. Arylpiperazine-mediated activation of Akt protects SH-SY5Y neuroblastoma cells from 6-hydroxydopamine-induced apoptotic and autophagic death. Tovilovic G, Zogovic N, Soskic V, Schrattenholz A, Kostic-Rajacic S, Misirkic-Marjanovic M, Janjetovic K, Vucicevic L, Arsikin K, Harhaji-Trajkovic L, Trajkovic V, Neuropharmacology 2013 72 224 235 23643751
49. Emerging role of autophagy in pediatric neurodegenerative and neurometabolic diseases. Ebrahimi-Fakhari D, Wahlster L, Hoffmann GF, Kolker S, Pediatr Res 2013 75 217 226 24165736
50. Neuronal Autophagy and Neurodevelopmental Disorders. Lee KM, Hwang SK, Lee JA, Exp Neurobiol 2013 22 133 142 10.5607/en.2013.22.3.133 24167408
51. dSarm/Sarm1 is required for activation of an injury-induced axon death pathway. Osterloh JM, Yang J, Rooney TM, Fox AN, Adalbert R, Powell EH, Sheehan AE, Avery MA, Hackett R, Logan MA, MacDonald JM, Ziegenfuss JS, Milde S, Hou YJ, Nathan C, Ding A, Brown RH Jr, Conforti L, Coleman M, Tessier-Lavigne M, Züchner S, Freeman MR, Science 2012 337 481 484 10.1126/science.1223899 22678360
52. Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Park KK, Liu K, Hu Y, Smith PD, Wang C, Cai B, Xu B, Connolly L, Kramvis I, Sahin M, He Z, Science 2008 322 963 966 10.1126/science.1161566 18988856
53. PTEN/mTOR and axon regeneration. Park KK, Liu K, Hu Y, Kanter JL, He Z, Exp Neurol 2010 223 45 50 10.1016/j.expneurol.2009.12.032 20079353